Development of Immunotherapy for Leukemia

Foundational Rales of Immunotherapy for Leukemia

As research has progressed, various treatments have been developed for the treatment of leukemia. In recent years, the significance of immunotherapy in the treatment of leukemia, lymphoma, and multiple myeloma has been steadily increasing. Various specialized forms of immunotherapy, such as checkpoint inhibitors, therapeutic vaccines, antibodies, and cell-based therapies, are employed to enhance the treatment outcomes for hematological malignancies. For instance, inotuzumab ozogamicin has demonstrated superior efficacy compared to standard chemotherapy in the treatment of acute lymphoblastic leukemia.

Fig. 1. Overview of the immune-based therapeutic approaches under investigation. (Barbullushi, K. et al., 2022)

Our Services

Alfa Cytology is a leading CRO specializing in developing immunotherapies for leukemia. The services we provide include checkpoint inhibitors, bispecific antibodies, therapeutic monoclonal antibodies, cancer vaccines, and cell therapies. Furthermore, our expertise lies in the evaluation of novel immuno-oncology therapies, as well as single and combination therapies across various treatments. Our ultimate goal is to identify highly effective treatments for leukemia.

We provide an extensive array of services dedicated to accelerating the development of your leukemia immunotherapy.

Discovery of Therapeutic Monoclonal Antibodies for Leukemia

We specialize in the customized development and manufacturing of monoclonal antibodies, offering tailored solutions for the treatment of leukemia.

Development of CAR T Cell Therapy for Leukemia

We provide CAR molecular design services and evaluate their efficacy using leukemia models.

Discovery of Bispecific Antibodies for Leukemia

Based on an advanced antibody discovery platform, we deliver bispecific antibodies for leukemia that are unseen by other modalities alone.

Development of Vaccines for Leukemia

Our comprehensive range of services aims to investigate the viability of leukemia vaccines while expediting their development and research endeavors.

Development of Immune Checkpoint Inhibitors for Leukemia

We specialize in designing monoclonal antibodies targeting immune checkpoint molecules specific for leukemia, to provide highly effective immune checkpoint inhibitors.

Efficacy Evaluation of Immunotherapy

We can provide customers with comprehensive in vivo and in vitro efficacy evaluation services for leukemia immunotherapies, which can meet your diverse testing needs.

Advantages of Our Services

Rapid production of antibodies
Highest quality for antibody production
Extensive experience in experimental design
Various leukemia models
High standards of animal experimentation
Cutting-edge CAR T cell preparation process

With Alfa Cytology' expertise and comprehensive range of services, we are dedicated to accelerating the advancement of innovative immunotherapeutic solutions for leukemia treatment. Please contact us if you have any special requirements about our services.

Reference

Barbullushi, K.; et al. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers. 2022, 14(12): 2994.

For research use only. Not intended for any clinical use.